Joseph Manning - Abbott Laboratories President
| ABTT34 Stock | BRL 46.69 0.25 0.45% |
President
Mr. Joseph Manning is Senior Vice President Abbott Nutrition International of the Company. From 2015 to 2017 he was Vice President, Nutrition, Asia Pacific. From 2014 to 2015 he was General Manager, Indonesia, Nutritional Products. From 2009 to 2014 he was General Manager, Russia, Nutritional Products. since 2017.
| Age | 50 |
| Tenure | 7 years |
| Phone | 224 667 6100 |
| Web | https://www.abbott.com |
Abbott Laboratories Management Efficiency
The company has return on total asset (ROA) of 0.0882 % which means that it generated a profit of $0.0882 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1928 %, meaning that it generated $0.1928 on every $100 dollars invested by stockholders. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 17.3 B in total debt with debt to equity ratio (D/E) of 0.55, which is about average as compared to similar companies. Abbott Laboratories has a current ratio of 1.72, which is within standard range for the sector. Debt can assist Abbott Laboratories until it has trouble settling it off, either with new capital or with free cash flow. So, Abbott Laboratories' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Abbott Laboratories sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Abbott to invest in growth at high rates of return. When we think about Abbott Laboratories' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Craig Silliman | Verizon Communications | 51 | |
| Roy Chestnutt | Verizon Communications | 53 | |
| Kyle Malady | Verizon Communications | 55 | |
| John Stratton | Verizon Communications | 54 | |
| John Bickham | Charter Communications | 69 | |
| Matthew Ellis | Verizon Communications | 52 | |
| Roger Gurnani | Verizon Communications | 55 | |
| Mike Stefanski | Verizon Communications | N/A | |
| Marni Walden | Verizon Communications | 48 | |
| Rima Qureshi | Verizon Communications | 54 | |
| Daniel Mead | Verizon Communications | 60 | |
| Stephanie Mitchko | Charter Communications | 53 | |
| Brady Connor | Verizon Communications | N/A | |
| Richard DiGeronimo | Charter Communications | 45 | |
| Hans Vestberg | Verizon Communications | 58 | |
| Anthony Skiadas | Verizon Communications | 50 | |
| Gregory Tomb | Zoom Video Communications | 57 | |
| Chris Bartlett | Verizon Communications | N/A | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 |
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Scott, Independent Director | ||
| Christopher Scoggins, Senior Vice President - Rapid Diagnostics | ||
| Roger Bird, Senior Vice President - U.S. Nutrition | ||
| Michael Dale, Senior Vice President - Structural Heart | ||
| Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Heather Mason, Senior Vice President - Abbott Diabetes Care | ||
| James Farrell, Independent Director | ||
| Phebe Novakovic, Independent Director | ||
| JeanYves Pavee, Senior Vice President - Established Pharmaceuticals, Developed Markets | ||
| Roxanne Austin, Independent Director | ||
| Stephen Fussell, Senior Vice President - Human Resources | ||
| Sally Blount, Independent Director | ||
| Daniel Starks, Independent Director | ||
| Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure | ||
| Thomas Frinzi, Senior Vice President - Abbott Medical Optics | ||
| Lisa Earnhardt, Executive Vice President - Medical Devices | ||
| Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America | ||
| Robert Alpern, Independent Director | ||
| Murthy Simhambhatla, Senior Vice President - Abbott Medical Optics | ||
| Glenn Tilton, Independent Director | ||
| Darren McDew, Independent Director | ||
| Richard Ashley, Executive VP of Corporate Devel. | ||
| Michael Rousseau, President - Cardiovascular and Neuromodulation | ||
| Charles Brynelsen, Senior Vice President - Abbott Vascular | ||
| Hubert Allen, Executive Vice President, General Counsel, Secretary | ||
| Charles Foltz, Senior Vice President - Abbott Vascular | ||
| Brian Yoor, Chief Financial Officer, Executive Vice President - Finance | ||
| John Ginascol, Executive Vice President - Core Diagnostics | ||
| Jared Watkin, Senior Vice President - Diabetes Care | ||
| Brian Blaser, Executive VP of Diagnostic Products | ||
| Scott White, Senior Vice President - International Nutrition | ||
| Deepak Nath, Senior Vice President - Abbott Vascular | ||
| Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
| Mary Moreland, Executive Vice President of Human Resources | ||
| Nancy McKinstry, Independent Director | ||
| Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Georges Vos, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Thomas Freyman, Executive VP of Fin. and Admin. | ||
| Randel Woodgrift, Senior Vice President - CRM | ||
| Michelle Kumbier, Independent Director | ||
| Eric Fain, Senior Vice President Group President - Cardiovascular and Neuromodulation | ||
| John Capek, Executive Vice President - Ventures | ||
| Miles White, Chairman, CEO and Chairman of Executive Committee | ||
| Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director | ||
| Elaine Leavenworth, VP Officer | ||
| Edward Liddy, Independent Director | ||
| John Stratton, Independent Director | ||
| Joseph Manning, Senior Vice President - Abbott Nutrition International | ||
| Scott Leinenweber, Licensing Relations | ||
| James Young, VP Officer | ||
| William Osborn, Lead Independent Director | ||
| Michael Warmuth, Executive Vice President - Established Pharmaceuticals | ||
| Robert Funck, Chief Financial Officer, Executive Vice President - Finance | ||
| Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America. | ||
| Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics | ||
| Melissa Brotz, VP Marketing |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.0882 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.07 T | |||
| Shares Outstanding | 20.92 B | |||
| Price To Earning | 40.47 X | |||
| Price To Book | 5.41 X | |||
| Price To Sales | 22.38 X | |||
| Revenue | 43.65 B |
Pair Trading with Abbott Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.Moving together with Abbott Stock
| 0.67 | DTCY3 | DTCOM Direct | PairCorr |
The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.
The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Abbott Stock refer to our How to Trade Abbott Stock guide.Note that the Abbott Laboratories information on this page should be used as a complementary analysis to other Abbott Laboratories' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Abbott Stock analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Global Correlations Find global opportunities by holding instruments from different markets |